Latest News - Alnylam Pharmaceuticals
Top Corporates Hub
Alnylam Pharmaceuticals
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
07.04.2026 13:09
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
07.04.2026 08:02
U.S. stock futures down, Nasdaq 100 falls over 100 points. Mach Natural Resources LP (MNR) shares dip 7.6% in pre-market trading.
Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now
31.03.2026 15:06
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best high growth healthcare stocks to buy now. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced on March 24 a set of strategic efforts aimed at accelerating earlier recognition and improving care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The company is advancing, through […]
Three Stocks That Could Be Trading Below Estimated Value In March 2026
31.03.2026 11:38
The United States market has experienced a 3.5% decline over the past week, yet it remains up by 14% over the last year, with earnings projected to grow by 15% annually. In this context, finding stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on long-term growth prospects amidst fluctuating market conditions.
3 Stocks That May Be Trading Up To 43.2% Below Intrinsic Value Estimates
30.03.2026 11:38
Over the last 7 days, the United States market has experienced a 1.9% decline, yet it remains up by 15% over the past year with earnings projected to grow by 15% annually. In such conditions, identifying stocks that may be trading below their intrinsic value can present potential opportunities for investors seeking to capitalize on undervalued assets in a growing market.
3 Stocks Trading Below Estimated Intrinsic Value By Up To 46.8%
26.03.2026 17:38
In the last week, the United States market has stayed flat, although it is up 16% over the past year with earnings forecasted to grow by 16% annually. In this environment, identifying stocks trading below their estimated intrinsic value can present opportunities for investors seeking potential growth at a reasonable price.
Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?
26.03.2026 15:30
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies
26.03.2026 07:27
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best rebound stocks to buy right now. On March 2, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) outlined its growth strategy at the TD Cowen 46th Annual Health Care Conference, emphasizing significant revenue expansion and ongoing innovation in RNAi therapies. The company expects revenue of around $4.4 billion to $4.7 billion […]
3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 40
25.03.2026 11:38
Over the last 7 days, the United States market has experienced a 2.3% drop, yet it remains up by 13% over the past year with earnings projected to grow by 16% annually. In this context, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking to capitalize on potential long-term gains amidst fluctuating market conditions.
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
23.03.2026 11:30
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents significant outcome for Arbutus and Genevant Two additional patients from Phase 2a clinical trials of imdusiran achieve functional cure Milestone payment received under Alnylam LNP license for product candidate to treat hepatocellular carcinoma (HCC) WARMINSTER, Pa., March 23, 202
Is Incyte Stock Outperforming the Dow?
20.03.2026 12:46
Incyte has outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.
Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More
16.03.2026 11:38
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, “Fool me once, shame on you; fool me twice, shame on me.” Well, the buy-the-dip crowd continued to get a masterclass in just that lesson on Friday. Once again, the stock market opened higher, and ... Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal
12.03.2026 11:13
In early March 2026, Tenaya Therapeutics reported a reduced full-year net loss of US$90.6 million and highlighted encouraging preclinical and Phase 1 data for its HDAC6 inhibitor TN-301 in Duchenne muscular dystrophy and cardiomyopathy, alongside a new research collaboration with Alnylam Pharmaceuticals in cardiovascular genetics. The comparison of TN-301 against the approved pan-HDAC inhibitor givinostat, showing stronger preclinical muscle and cardiac effects without similar side-effect...
Alnylam to Webcast TTR Investor Webinar
10.03.2026 12:00
CAMBRIDGE, Mass., March 10, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event.
Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation
07.03.2026 17:09
Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi year research collaboration with Tenaya Therapeutics focused on RNAi based therapeutics for cardiovascular diseases. The agreement covers up to 15 novel genetic targets and includes milestone payment structures that indicate material relevance for Alnylam's business development plans. For context, Alnylam is known for its RNA interference platform, with a focus on genetic and rare diseases. Cardiovascular disease is a large and...
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness
07.03.2026 07:07
Event-driven snapshot of Alnylam Pharmaceuticals Alnylam Pharmaceuticals (ALNY) has drawn investor attention following fresh scrutiny of its recent share performance, with the stock showing a 1-day return near flat and weaker moves over the past week and month. See our latest analysis for Alnylam Pharmaceuticals. While the latest share price of US$320.66 comes after a 90 day share price return of about a 30% decline and a year to date share price return of about a 20% decline, the 1 year...
Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development
05.03.2026 14:05
Helix, the leading enterprise genomics company, today announced a multi-year relationship with Alnylam, the leading RNAi therapeutics company. This agreement provides Alnylam access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas.
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
05.03.2026 13:30
Agreement Combines Tenaya’s Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potent
Tenaya Therapeutics Collaborates With Alnylam Pharmaceuticals To Discover Human Genetic Targets For Potential Development Of Disease-modifying Treatments For Cardiovascular Diseases
05.03.2026 09:34
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease,
Is Canada’s AMVUTTRA Reimbursement Tailwind Altering The Investment Case For Alnylam Pharmaceuticals (ALNY)?
05.03.2026 08:13
Alnylam Pharmaceuticals recently received a positive reimbursement recommendation in Canada for its RNAi therapy AMVUTTRA in transthyretin-mediated amyloid cardiomyopathy, backed by Phase 3 HELIOS-B data showing benefits across key clinical endpoints. This combination of expanded public access, strong clinical validation, rapid AMVUTTRA uptake, and cardiovascular pipeline progress could meaningfully influence how investors view Alnylam’s growth profile and risk balance. We’ll now examine how...